MENU
+Compare
CRDF
Stock ticker: NASDAQ
AS OF
Sep 3 closing price
Price
$1.96
Change
+$0.01 (+0.51%)
Capitalization
130.72M

CRDF stock forecast, quote, news & analysis

Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need... Show more

CRDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. CRDF showed earnings on July 29, 2025. You can read more about the earnings report here.
Interact to see
Advertisement
A.I.Advisor
a Summary for CRDF with price predictions
Sep 03, 2025

CRDF's RSI Indicator remains in oversold zone for 6 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for CRDF just turned positive on August 22, 2025. Looking at past instances where CRDF's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CRDF advanced for three days, in of 245 cases, the price rose further within the following month. The odds of a continued upward trend are .

CRDF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 15, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on CRDF as a result. In of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The 10-day moving average for CRDF crossed bearishly below the 50-day moving average on August 01, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

The 50-day moving average for CRDF moved below the 200-day moving average on August 15, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRDF declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for CRDF entered a downward trend on September 03, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.231) is normal, around the industry mean (19.946). P/E Ratio (0.000) is within average values for comparable stocks, (51.910). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.076). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (212.766) is also within normal values, averaging (324.828).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CRDF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRDF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Moderna (NASDAQ:MRNA), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 1.88B. The market cap for tickers in the group ranges from 31.65 to 101.69B. VRTX holds the highest valuation in this group at 101.69B. The lowest valued company is CYCCP at 31.65.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 0%. For the same Industry, the average monthly price growth was 15%, and the average quarterly price growth was 31%. RLMD experienced the highest price growth at 120%, while OTLK experienced the biggest fall at -63%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -40%. For the same stocks of the Industry, the average monthly volume growth was -22% and the average quarterly volume growth was 32%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 82
Price Growth Rating: 56
SMR Rating: 93
Profit Risk Rating: 94
Seasonality Score: -20 (-100 ... +100)
View a ticker or compare two or three
CRDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a cancer medicine oncology therapeutics company, which engages in the development of drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, lymphomas, and solid tumors

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
11055 Flintkote Avenue
Phone
+1 858 952-7570
Employees
32
Web
https://www.cardiffoncology.com